VFA
BMRN icon

Valeo Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Valeo Financial Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,123
Closed -$311K – 683
2021
Q1 		$311K Sell
4,123
-150
-4% -$12.3K 0.01% 347
2020
Q4 		$375K Buy
4,273
+3,623
+557% +$287K 0.02% 292
2020
Q3 		$49K Buy
650
+95
+17% +$9.61K ﹤0.01% 673
2020
Q2 		$68K Sell
555
-395
-42% -$39.3K 0.01% 620
2020
Q1 		$76K Sell
950
-774
-45% -$66.7K 0.01% 484
2019
Q4 		$146K Buy
1,724
+500
+41% +$37.8K 0.01% 384
2019
Q3 		$82K Buy
1,224
+6
+0.5% +$462 0.01% 477
2019
Q2 		$104K Buy
1,218
+1,200
+6,667% +$103K 0.01% 425
2019
Q1 		$2K Sell
18
-41
-69% -$3.8K ﹤0.01% 1336
2018
Q4 		$5K Hold
59
– – ﹤0.01% 1059
2018
Q3 		$5K Hold
59
– – ﹤0.01% 1176
2018
Q2 		$6K Buy
+59
New +$5.17K ﹤0.01% 1073
2018
Q1 		– Sell
-52
Closed -$5K – 1540
2017
Q4 		$5K Sell
52
-13
-20% -$1.13K ﹤0.01% 993
2017
Q3 		$6K Buy
+65
New +$5.74K ﹤0.01% 818

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Valeo Financial Advisors's BMRN Position: Q2 2021 in Review

Valeo Financial Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2021, closing a stake of 4,123 shares — an estimated $311K sold.

Valeo Financial Advisors first reported a position in BMRN in Q3 2017 and held it in 14 quarters. The position peaked at $375K in Q4 2020. 529 funds tracked by Wall St. Rank hold BMRN as of Q2 2021.

  • Valeo Financial Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 4,123 BioMarin Pharmaceuticals shares in Q2 2021, an estimated $311K.
  • Valeo Financial Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2017 and held it in 14 quarters.
  • Valeo Financial Advisors's BioMarin Pharmaceuticals position peaked at $375K in Q4 2020.
  • 529 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.